Braveheart Bio (NASDAQ:BRVE) Hits New 52-Week Low – What’s Next?

Shares of Braveheart Bio, Inc. (NASDAQ:BRVE) reached a new 52-week low during trading on Thursday. The stock traded as low as $17.42 and last traded at $17.5240, with a volume of 33,143 shares. The stock had previously closed at $20.10.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on BRVE. Wall Street Zen upgraded shares of Braveheart Bio to a “hold” rating in a report on Saturday, August 15th. Zacks Research raised shares of Braveheart Bio to a “hold” rating in a research note on Tuesday, September 1st. Jefferies Financial Group started coverage on shares of Braveheart Bio in a report on Monday, August 31st. They issued a “buy” rating and a $48.00 price objective for the company. TD Cowen started coverage on shares of Braveheart Bio in a research report on Monday, August 31st. They set a “buy” rating on the stock. Finally, Stifel Nicolaus initiated coverage on Braveheart Bio in a report on Monday, August 31st. They set a “buy” rating and a $45.00 target price on the stock. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $45.25.

Braveheart Bio Stock Up 6.8%

The company has a market capitalization of $1.67 billion and a PE ratio of -7.41. The stock’s fifty day simple moving average is $22.72.

Braveheart Bio (NASDAQ:BRVE) last posted its quarterly earnings results on Tuesday, September 8th. The company reported ($2.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($2.26). Equities analysts anticipate that Braveheart Bio, Inc. will post -1.99 EPS for the current year.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.